The lab oddity prevails: Discovery of Pan-CDK inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY1000394) for the treatment of cancer
Lead optimization of a high-throughput screening hit led to the rapid identification of aminopyrimidine ZK304709, a multitargeted CDK and VEGF-R inhibitor that displayed a promising preclinical profile. Nevertheless, ZK304709 failed in phaseI studies due
Get Best Price for1223498-32-5(RS)-S-ethyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]amino}-5-(trifluoromethyl)-pyrimidin-2-yl]amino}phenyl)sulfoximide